Early results from a phase 1 clinical trial of CAR T cells administered directly into the chest cavity for the treatment of pleural cancers has shown low toxicity and high efficacy.
The results of this study were independent of whether MET positivity by immunohistochemistry was determined using an H-score cutoff of 300 or at least 200.
For patients with advanced lung cancer characterized by an EGFR-activating mutation that has progressed on osimertinib, treatment decision making is challenging.
303 the number needed to screen in extended follow-up of National Lung Screening Trial.
Higher rate of treatment failure for lung cancer patients with high Deep Profiler scores.
Machine learning algorithm detected 7 types of cancer in liquid biopsy and identified tissue of disease origin.
Researchers retrospectively assessed the relationship between tumor mutation burden and specific EGFR alterations.
Upfront NGS saves time and money compared with the sequential use of individual gene tests for patients with metastatic lung cancer, according to study authors.
One potentially revolutionary hypothesis relates to the evolutionary processes involved in oncogenesis.
Combination of clinical and radiologic factors can reliably predict risk for incident lung cancer.
